使用抗高血压药物的患者的早期植入失败:一项回顾性队列研究
Daya Masri1, Dror Bar-Hai1, Hiba Masri-Iraqi2
1Department of Oral and Maxillofacial Surgery, Rabin Medical Center, Campus Beilinson, Petah Tiqwa, Israel.
International dental journal
|July 19, 2024
概括
抗高血压药物可以通过减少早期植入物失败来改善牙植入物的成功. 这项研究发现,服用这些药物的患者失败率较低,这表明对骨质整合有潜在的益处.
科学领域:
- 牙科植入物学 牙科植入物学
- 药理学 药理学是指药理学的学科.
- 骨生物学 骨生物学 骨生物学
背景情况:
- 已知抗高血压药物可促进骨质母细胞分化和骨矿物质形成.
- 牙植入物的骨质整合依赖于新的骨形成和重塑过程.
- 这表明,在使用抗高血压药物的患者中,可能有改善骨质整合的潜力.
研究的目的:
- 评估抗高血压药物对牙植入物的骨质整合的影响.
- 评估在服用抗高血压药物或不服用抗高血压药物的患者中早期植入物失败 (EIF) 率.
主要方法:
- 一项回顾性队列研究,涉及792名患者,他们在6年内接受了牙科植入物.
- 患者被分为正常血压 (NT),有药物的高血压 (HTN + med) 和没有药物的高血压 (HTN - med) 组.
- 早期植入失败 (EIF),定义为负载后12个月内失败,是主要的结果指标.
主要成果:
- 没有药物治疗的高血压组 (HTN-med) 呈现出最高的EIF率 (28.60%).
- 抗高血压药物组 (HTN + med) 的EIF率明显较低 (9.70%) 与正常血压组 (14.50%) 相比.
- 对植入物数据的分析显示,HTN + med组的EIF率 (2.29%) 与NT组 (4.33%) 相比,HTN + med组的EIF率明显较低.
结论:
- 抗高血压药物与早期植入物失败率的统计显著降低有关.
- 这些发现表明,抗高血压药物可能会积极影响牙植入物的骨质整合.
- 鼓励临床医生考虑为高血压患者提供植入式假肢,以确保良好的药物服药.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
418
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
418
Errors occurring during blood pressure monitoring
675
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Several factors...
675
Antihypertensive Drugs: Direct Renin Inhibitors
538
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
538
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
594
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
594
Heart Failure Drugs: Diuretics
361
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
361
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
150
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
150


